RecruitingPhase 1NCT07364513

Phase 1b Safety Study of IMSB301 in Type 1 Interferonopathies

A Phase 1b Open-Label Study of IMSB301 in Subjects With a Type 1 Interferonopathy

Sponsor

ImmuneSensor Therapeutics Inc.

Enrollment

6 participants

Start Date

Jan 12, 2026

Study Type

INTERVENTIONAL

Conditions

Type 1 Interferonopathies

Summary

Open-Label Study (Phase Ib) of Type 1 Interferonopathy patients receiving IMSB301 monotherapy.

Eligibility

Min Age: 12 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called IMSB301 for people with type 1 interferonopathies. The study is currently recruiting participants at 1 location. People eligible for this study include aged 12 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIMSB301

Twice daily administration for 28 days. Subjects will be treated as out-patient and will return to the clinic at least once weekly on Days 8, 15, 22 and 29. Continued treatment beyond Day 28 may be considered on a case-by-case basis for subjects benefiting from treatment.

Locations(1)

The Children's Hospital at Westmead

Sydney, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07364513